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Abstract
Zygomycosis constitutes the third leading cause of invasive fungal infections following aspergillosis and candidosis. Patients with haema-
tologic malignancies or haematopoietic stem cell transplantation are particularly susceptible to zygomycosis. Neutropenia represents the
most important pathogenic mechanism inﬂuencing the onset and outcome of zygomycosis. Neutrophils cause a lesion of the fungal wall
with subsequent destruction by macrophages. They also enhance the activity of antifungal drugs against Zygomycetes. Strategies that
aim to increase neutrophil count and function, such as granulocyte colony stimulating factor and granulocyte transfusion, could play an
important role in the management of this life-threatening infectious complication.
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Introduction
Zygomycosis is seen with increasing incidence, particularly in
patients with haematological malignancies (HM) or haemato-
poietic stem cell transplantation (HSCT) [1,2]. It represents
the third leading cause of invasive fungal infections (IFI) fol-
lowing aspergillosis and candidiasis [1]. The pathogens caus-
ing these infections have a marked capability for vascular
invasion and rapidly result in thrombosis and tissue necrosis.
Pathogenic mechanisms mediating vascular infection are
varied and include high acidosis of the substratum, macro-
phage inhibition in controlling spores germination, reduced
production of oxidative metabolites by respiratory phago-
cytes, impaired neutrophil chemotaxis and immunosuppres-
sive therapy. In particular, neutropenia represents the most
important pathogenic mechanism inﬂuencing both the onset
and outcome of zygomycosis.
The Role of Neutrophils
Neutrophils are paramount in the control of fungal infec-
tions because they are essential in the initiation and execu-
tion of the acute inﬂammatory response and the
subsequent resolution of fungal infection. Usually, neutro-
phils, together with macrophages, internalize resting or
swollen conidia and use mechanisms such as the respiratory
burst to combat IFI [3]. Unfortunately, they cannot ingest
the majority of Zygomycetes because of the large size of
the hyphae, but they do damage and subsequently destroy
them [2].
Recently, it has been demonstrated that normal human
neutrophils exhibit reduced hyphal damage, associated with
impaired superoxide anion release, following exposure to
Rhizopus oryzae compared with that seen with Aspergillus fu-
migatus [4]. This attenuated efﬁcacy of human neutrophils
against Zygomycetes may explain the higher pathogenicity of
these fungi. By contrast, it has been found that, similar to
A. fumigatus, R. oryzae hyphae selectively induce upregulation
in several pro-inﬂammatory genes and in toll-like receptor
(TRL)-2 mRNA activation. These are important components
of the immune system which activate signalling events induc-
ing the expression of effector molecules such as cytokines
and chemokines.
The expression of the antifungal effector functions of
neutrophils seems to occur through the involvement of dis-
tinct members of the TRL family. Their expression appears
to be modulated by different formulations of amphotericin
B (AmB), with superiority of liposomal AmB (L-AmB)
favouring the expression of TLR-4 and anti-inﬂammatory
genes over that of TRL-2 in neutrophils exposed to
A. fumigatus [5].
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The Role of Neutropenia
It is well known that the longer and more severe the neu-
tropenia, the higher the incidence of serious infections,
including IFI. In 1966, Bodey et al. [6] demonstrated that the
presence of infections in patients with HM and, above all,
acute leukaemia is related to the levels of circulating leuko-
cytes, especially neutrophils, and that increased levels of neu-
trophils decrease the prevalence of all types of infections.
The most important factor in predicting the risk of fungal
infection is the duration of neutropenia; a 60% risk of devel-
oping infection is reported if neutropenia persists for
3 weeks and this rises to 100% when the neutrophil count is
<0.10 · 109/L. The incidence of infections is not the only
aspect related to the neutrophil count; it also affects the
outcome and the highest incidence of death occurs among
patients with persistent severe neutropenia (<0.10 · 109/L)
when there is also a larger number of invasive fungal infec-
tions [6].
Various conditions can induce neutropenia, such as cancer,
radiation therapy, autoimmune diseases, HIV and haemato-
logical malignancies. Patients affected by acute myeloid leu-
kaemia are at highest risk for zygomycosis [1]. These
patients become neutropenic as a result of both bone mar-
row invasion by leukaemic cells and the use of myeloablative
treatments for the underlying HM.
The multiple clinical series reported in the literature on
zygomycosis and HM show that zygomycosis mainly occurs
in neutropenic patients: 71–100% of zygomycosis patients
have neutropenia and the median duration of neutropenia
ranges from 12 to 16 days (Table 1) [1,7–11].
A case-control observational study comparing patients
with zygomycosis with those with invasive aspergillosis (IA)
and healthy controls found a non-statistically signiﬁcant trend
toward more frequent neutropenia at the time of diagnosis
in the IA group (p = 0.06), and a non-statistically signiﬁcant
duration of neutropenia before diagnosis (p = 0.06) [11]. A
comparison of zygomycosis patients with controls found that
prolonged neutropenia (>10 days) at the time of diagnosis
rather than a low neutrophil count (<0.50 · 109/L) is more
common in patients with zygomycosis (p = 0.05) [11].
Neutropenia inﬂuences not only the onset of the fungal
complication, but also the outcome. In all the reported ser-
ies, univariate analyses have shown that recovery from neu-
tropenia is statistically correlated with an improvement in
the infection (Table 2) [1,7–11]. However, multivariate analy-
sis has repeatedly shown that the signiﬁcance is lost, and the
only factors which correlate with a favourable outcome
remain antifungal treatment with L-AmB and length of ther-
apy [1–11]. Furthermore, neutrophils have an additional
action against fungi through improvements in the activity of
some antifungal drugs. In a recent in vitro study, in the pres-
ence of neutrophils even drugs with a low efﬁcacy against
Zygomycetes, like voriconazole, seem able to damage less
pathogenic species, such as Absidia [12].
The Use of Growth Factors
To overcome neutropenia during IFI, the use of growth
factors or the granulocyte colony stimulating factor (G-CSF)-
mobilized granulocyte transfusions (GTX) has been sug-
gested. G-CSF and granulocyte-macrophage CSF (GM-CSF)
are haematopoietic growth factors usually produced by
monocytes, ﬁbroblasts and endothelial cells. They act on
neutrophil progenitor cells by binding to speciﬁc cell surface
receptors and thereby stimulate the proliferation, differentia-
tion, commitment and maturation of granulocyte precursor
cells. These growth factors, particularly GM-CSF but also
other cytokines like interferon-c, are able to augment
TABLE 1. Neutropenia as a principal risk factor for













Pagano et al. 1997 [7] 33/37 89 14
Kontoyiannis et al. 2000 [8] 17/24 71 16
Pagano et al. 2004 [1] 47/59 80 12
Bethge et al. 2005 [9] 6/6 100 10
Kara et al. 2007 [10] 16/20 80 10
TABLE 2. Prognostic role of recovery from neutropenia in
haematological malignancies: results of univariate analysis














Pagano et al. 1997 [7] 9/28 9/9 <0.00002
Kontoyiannis et al. 2000 [8] 0/9 5/12 <0.01
Pagano et al. 2004 [1] 16/46 6/13 0.01
Kara et al. 2009 [10] NR NR 0.01
NR, not reported.
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neutrophil-induced hyphal damage of Zygomycetes in a time-
dependent manner. In particular, it has been recently demon-
strated that human neutrophils show a reduced capacity to
mount an oxidative burst in response to Rhizopus species,
such as oryzae and microsporus, in comparison with their
response to Absidia corymbifera. However, neutrophils after
incubation with interferon-c, GM-CSF or their combination
exhibit a signiﬁcantly increased capacity to induce hyphal
damage of all Zygomycetes. This effect is time-dependent,
requiring the prolonged incubation of neutrophils with cyto-
kines, and may suggest a role for GM-CSF and interferon-c
in the management of invasive zygomycosis [13].
Regarding the clinical applications of these agents, more
information on the use of G-CSF is available. G-CSF has
been administered to overcome the neutropenic state after
aggressive chemotherapy or HSCT; some series have been
reported, but have not shown signiﬁcant correlations
[1,7,8,10]. By contrast, a large literature review has demon-
strated that the majority of patients (15/18, 83%) in whom
G-CSF was added to antifungal therapy showed an improve-
ment in their clinical condition [14]. Of course, these last
results may have been inﬂuenced by selection bias arising
from the publication of only patients with a favourable out-
come.
Granulocyte Transfusion
The transfusion of granulocytes (GTX) in neutropenic recipi-
ents represents a logical approach to overcoming the tempo-
rary deﬁciency of neutrophils, particularly in patients with IFI.
GTX was tested in two different settings: interventional and
prophylactic. It has been utilized in patients with sepsis
caused by Candida spp. [15,16] or invasive aspergillosis [17–
20], with better results in the ﬁrst category of patients.
Experience in patients with zygomycosis is limited and is
chieﬂy characterized by sporadic case reports, as demon-
strated in the main literature reviews [14,21]. The larger ser-
ies in which GTX was used (ﬁve cases) in neutropenic
patients with HM and life-threatening infections suggested
that a better role for this procedure might be as secondary
prophylaxis during neutropenia after aggressive chemother-
apy [20].
Conclusions
Neutropenia represents the major predisposing factor for
zygomycosis in HM. Despite recent progress in the manage-
ment of other mould infections (i.e. aspergillosis), the prog-
nosis in zygomycosis continues to be unfavourable. This
probably reﬂects the difﬁculties involved in diagnosing this
complication and the intrinsic resistance of Zygomycetes to
many antifungal drugs. Given this scenario, improvements in
clinical status appear to be closely related to the role of neu-
trophils, which we consider to be more relevant than in
other fungal infections. Together with surgical debridement,
whenever applicable, and antifungal therapy (i.e. L-AmB and
posaconazole [6,22]), strategies which aim to increase the
neutrophil count and function, such as G-CSF and GTX, may
play an important role in the management of this life-threat-
ening infection.
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